Oral Decitabine and Tetrahydrouridine

Phase 2Small molecule

CClinical Hub for Interventional Research (CHOIR)

Oral Decitabine and Tetrahydrouridine is one of 16 small molecule programs targeting High Risk. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

High RiskNot yet recruiting

High RiskPhase 2

Not yet recruiting

Competition

Competitive Landscape

16 competitors in High Risk

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

1 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 4

Taxotere

AAvyxa

Phase 3

1 5

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 6

Opdivo

Bristol-Myers Squibb

Phase 2

3 7

Dacogen

Sun Pharmaceutical Industries, Inc.

Phase 2

3 8

Calquence

AstraZeneca

Phase 2

1 9

Rituxan

Roche

Phase 2

1 10

Rydapt

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Not yet recruiting

High Risk

NCT07435636

Clinical

Trials by Indication[1]

Sickle Cell Disease1 trial

Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease

Completed·YYogen Saunthararajah·Phase 1·NCT01685515·25 enrolled

High Risk1 trial

Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis

Not yet recruiting·CClinical Hub for Interventional Research (CHOIR)·Phase 2·NCT07435636·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Oral Decitabine and Tetrahydrouridine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oral Decitabine and Tetrahydrouridine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oral Decitabine and Tetrahydrouridine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clinical Hub for Interventional Research (CHOIR) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CClinical Hub for Interventional Research (CHOIR)

Oral Decitabine and Tetrahydrouridine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Sickle Cell Disease1 trial

High Risk1 trial

References

Drug Info

Quick Facts

Related News